The SAMMPRIS trial was funded by a research grant (U01 NS058728) from the US Public Health Service National Institute of Neurological Disorders and Stroke (NINDS). In addition, the following Clinical and Translational Science Awards, funded by the National Institutes of Health, provided local support for the evaluation of patients in the trial: Medical University of South Carolina (UL1RR029882), University of Florida (UL1RR029889), University of Cincinnati (UL1RR029890), and University of California, San Francisco (UL1RR024131).
Corporate Support: Stryker Neurovascular (formerly Boston Scientific Neurovascular) provided study devices and supplemental funding for third party device distribution, site monitoring and study auditing. This research is also supported by the Investigator-Sponsored Study Program of AstraZeneca that donates rosuvastatin (Crestor) to study patients.
Drs. Fiorella, Derdeyn, Turan, Janis, and Chimowitz, Michael Lynn M.S, and Bethany Lane RN serve on the Executive Committee of the SAMMPRIS trial which is funded by the National Institute of Neurological Disorders and Stroke (grant number: U01 NS058728). All receive salary support from the SAMMPRIS grant. All other authors were investigators in SAMMPRIS and were reimbursed from the SAMMPRIS grant for their effort. The following investigators report additional support:
David Fiorella MD, PhD has received institutional research support from Seimens Medical Imaging and Microvention, consulting fees from Codman/Johnson and Johnson, NFocus, W.L. Gore and Associates, and EV3/Covidien, and royalties from Codman/Johnson and Johnson. He has received honoraria from Scientia and has ownership interest in CVSL and Vascular Simulations.
Colin Derdeyn MD receives grant support from the NINDS (P50 55977; R01 NS051631). He is also on the Scientific Advisory Board for W.L Gore and Associates and is the Chair of the Scientific Advisory Board for Pulse Therapeutics.
Michael J. Lynn, MS receives grant support from the National Eye Institute. He is the principal investigator of the Coordinating Center for Infant Aphakia Treatment Study (EY013287) and a co-investigator on the Core Grant for Vision Research (EY006360).
Stanley L. Barnwell, MD PhD has been a consultant for Stryker Corporation.
Brian L. Hoh, MD has received research support from the NIH grant number 1K08NS067058-01. Dr. Hoh has served as an expert witness for several medical defense cases including two cases on an AVM embolism, one on a venous stent, and one on a subarachnoid hemorrhage.
Elad I. Levy, MD has received research support from Boston Scientific Corporation, Codman & Shurtleff Inc., and EV3 / Covidien. Dr. Levy has shareholder / ownership interest in Intratech Medical Ltd. and Mynx / Access Closure. Dr. Levy has acted as a consultant for Codman & Shurtleff Inc., TheraSyn Sensors Inc., and EV3 / Covidien. He has received honoraria payment from Boston Scientific Corporation. Dr. Levy has also received other financial / material support from Abbott Vascular and EV3 / Covidien. Dr. Levy has provided expertise in a legal review.
Richard P. Klucznik, MD has received payment for speakers’ bureau appointments from EV3 / Covidien and Microvention.
Cameron G. McDougall, MD has served on medical advisory boards for Covidien and W.L. Gore & Associates.
G. Lee Pride Jr, MD has received research support for the ACES and LVIS trials. Dr. Pride has received honoraria payment from the Texas Neurological Society (invited speaker) and ACOR (invited speaker).
Osama O. Zaidat, MD, MS has acted as a consultant for EV3 / Covidien, Codman Neurovascular, Stryker Corporation and Microvention.
Michael F. Waters, MD, PhD has received research support from an NIH K23 grant and an NIH Challenge Grant. Dr. Waters has provided expertise in a legal review.
J. Maurice Hourihane, MD has served as an expert witness in a medical defense case.
Andrei V. Alexandrov, MD has received research support from NINDS for the SPOTRIAS trial. Dr. Alexandrov has received honoraria payment for CME lectures. He has ownership interest with Cerevast Therapeutics and has also been involved with their consultant / advisory board.
Mark D. Johnson, MD has received research support for the IRIS, RESPECT and POINT trials.
Harry J. Cloft, MD, PhD has received research support for the SAPPHIRE Carotid Stent registry.
Bethany F. Lane RN has received consulting fees from Microvention Terumo.
Tanya N. Turan, MD is a past recipient of funding from the American Academy of Neurology (AAN) Foundation Clinical Research Training Fellowship and is the current recipient of a K23 grant from NIH/NINDS (1 K23 NS069668-01A1). She has also served as an expert witness in medical legal cases.
Scott Janis PhD is a program director at the National Institute of Neurological Disorders and Stroke.
Marc Chimowitz, MBChB has received research grants from NINDS to fund the WASID trial (1 R01 NS36643) and to fund other research on intracranial stenosis (1 K24 NS050307 and 1 R01 NS051688). He currently serves on the stroke adjudication committee of an industry funded osteoporosis drug trial (Merck and Co., Inc.) and on the DSMB of another industry funded patent foramen ovale closure trial (W.L Gore and Associates) and is compensated for those activities. He has also served as an expert witness in medical legal cases.